



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9/1  
1/30/03  
gnd

In the Application of:

Charles Maliszewski et al.

Docket No.: 2879-US

Serial No: 09/835,147

Group Art Unit: 1644

Filed: April 13, 2001

Examiner: A. Decloux

For: INHIBITORS OF PLATELET  
ACTIVATION AND RECRUITMENT

RECEIVED

JAN 28 2003

TECH CENTER 1600/2500

U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, VA 22202

**CERTIFICATE OF MAILING**  
I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on the date indicated below.  
BY Carmita Edwards  
DATE January 15, 2003

**AMENDMENT UNDER 37 CFR § 1.115**

This paper accompanies the Notice to Comply mailed 16 December 2002.

**AMENDMENT**

Please enter the following amendment. A marked up version of each replacement paragraph is shown in the Appendix entitled "VERSION WITH MARKINGS TO SHOW CHANGES."

**In the Specification**

Please replace the Sequence Listing (pgs. 1-34) with the attached new Sequence Listing (pgs. 1-39). Please replace the paragraph at page 13, line 32, to page 14, line 7 with the following paragraph:

The present invention comprises fusion polypeptides with or without spacer amino acid linking groups. For example, two soluble CD39 domains can be linked with a linker sequence, such as (Gly)<sub>4</sub>Ser(Gly)<sub>5</sub>Ser (SEQ ID NO:32), which is described in United States Patent 5,073,627. Other linker sequences include, for example, GlyAlaGlyGlyAlaGlySer(Gly)<sub>5</sub>Ser (SEQ ID NO:33), (Gly<sub>4</sub>Ser)<sub>2</sub> (SEQ ID NO:34), (GlyThrPro)<sub>3</sub> (SEQ ID NO:35), and (Gly<sub>4</sub>Ser)<sub>3</sub>Gly<sub>4</sub>SerGly<sub>5</sub>Ser (SEQ

21